Reading the Claim 1 verbatim of Advanced Polymer Systems Inc's Microsponge® retinol patent US5851538 (filed 1995-12, granted 1998-12) in cosmetic delivery context — the 'porous microsphere × retinol' delivery patent that sat silent for 23 years behind the candidates.tsv label 'CS-007 P&G niacinamide' (excavation memo)

About this memo: This memo is the reality reading of CS-007 US5851538, confirmed as a swap in ep76 (cosmetic-patent-04). Where Day 21's excavation note centered on 'DB correction tale,' this memo focuses on 'reading the actual patent's Claim 1 verbatim in cosmetic delivery context.' After confirming inventors, assignee, application date, and full Claim 1 from primary Google Patents retrieval, it organizes the Microsponge® lineage (Retin-A Micro / Differin Gel / Olay Total Effects et al.) and positions retinol delivery technology in modern skincare.

Patent identity

Sergio Nacht is a co-founder of APS (Advanced Polymer Systems Inc), with a dermatology / pharmacy (PharmD) background, long responsible for Microsponge® application development since the 1980s. Michael Froix appears (from inventor itemprop primary source only) to have a polymer chemistry background and led porous polymer particle synthesis; Masha Pukshansky led formulation work.

Claim 1 verbatim

1. A stable pharmaceutical composition for topical administration of retinol consisting of an oil-in-water emulsion comprising, suspended in the emulsion, solid water-insoluble microscopic particles containing a substantially continuous network of pores open to the exterior of the particles and a retinoid composition comprising retinol residing only in the pores, the composition causing lower irritancy when applied than a composition containing the same concentration of retinol in a non-(microscopic particle) formulation.

Decompose into seven elements.

1. Form: oil-in-water emulsion. → Typical cosmetic cream / lotion base, with oil phase and water phase emulsified by surfactant.
2. Microparticle properties: 'solid' / 'water-insoluble' / 'microscopic' particles. → APS Microsponge® is typically 5-300 µm diameter, made of polystyrene-divinylbenzene copolymer or methacrylate ester crosslinked polymer.
3. Pore network: 'substantially continuous network of pores.' → 'Sponge-like' pore structure penetrating the entire particle interior.
4. External pore opening: 'open to the exterior.' → Pores are not just closed cavities; open system enabling material exchange with the exterior.
5. Retinol-containing retinoid composition: retinoid composition contains retinol (all-trans-retinol, the pure form of vitamin A).
6. Retinol resides only within the pores: retinoid composition exists 'only within the pores.' → Dissolution of retinol in the emulsion's oil phase is excluded; retinol must be confined within the porous microparticle pores.
7. Lower irritancy comparison: 'lower irritancy' compared to a non-(microparticle) formulation of the same retinol concentration. → Not an efficacy claim, but a regulatory definition of formulation form superiority.

The narrowest of the seven is (6) retinol residing only in the pores. This means (a) forms where Microsponge is dispersed in an emulsion but additional retinol also dissolves in the oil phase can avoid Claim 1, and (b) only forms purely confining retinol in the porous microspheres are covered by Claim 1. Competitive space remained for follower delivery technologies.

Claims 2-16 overview

Claims 2-3 specify retinol concentration (0.001-20.0% w/w, preferably 0.01-5.0% w/w) and Microsponge concentration. Claims 4-9 specify physical parameters: particle size, pore size (typically 0.1-10 µm), pore volume (5-90% of particle weight), particle specific surface area (10-1000 m²/g). Claims 10-13 cover combinations with other actives (benzoyl peroxide, salicylic acid, hydroquinone, etc.). Claims 14-16 cover manufacturing methods (post-loading after Microsponge synthesis; or simultaneous synthesis / loading in liquid).

The most valuable in cosmetic delivery context is the physical parameter range in Claims 4-9 — whether commercial retinol formulations fall within this range determines the boundary of infringement / non-infringement of Claim 1. Since the patent is presumed expired since December 2018, modern high-concentration retinol products (The Ordinary Retinol 1%, La Roche-Posay Pure Retinol 0.3%, Olay Regenerist Retinol 24, etc.) can freely adopt Microsponge / Polytrap / Microcapsule delivery forms (this concerns this single patent only; related patents need separate verification).

Five product lineages of Microsponge® extension

The Microsponge® technology of US5851538 was licensed from APS to multiple pharmaceutical and cosmetic manufacturers, becoming the core delivery in five major products.

1. Retin-A Micro 0.1% gel (Ortho-McNeil, FDA approval 1997) — Tretinoin (all-trans retinoic acid, prescription pharmaceutical) confined in Microsponge. Significantly reduced irritation (erythema, peeling, dryness) compared to conventional Retin-A Cream 0.1%. First-line prescription for acne, rosacea, photoaging.
2. Differin Gel 0.1% (Galderma, FDA approval 1996) — Adapalene (third-generation retinoid) confined in Microsponge-similar delivery. OTC in the US since 2016 (purchasable without prescription). OTC gold standard for acne.
3. Olay Total Effects line (P&G / J&J system, 1999-) — Multi-benefit skincare integrating whitening, anti-aging, moisturizing. Retinyl propionate and other stabilized retinoid esters confined in Microsponge / Polytrap. Pioneer of Microsponge adoption in drugstore cosmetics.
4. RoC Retin-Ox (Johnson & Johnson subsidiary RoC brand, 1998-) — Retinol 0.05-0.5% confined in Microsponge / Polytrap. Microsponge adoption case in French pharmacy cosmetic brand.
5. 2010s high-concentration retinol face creams — The Ordinary Retinol 1% (DECIEM, 2017) / Paula's Choice 1% Retinol Booster (2010s) / La Roche-Posay Pure Retinol 0.3% (2018). Synchronization of Microsponge patent expiration (estimated 2018-12-22) with DECIEM's 'single-ingredient high-concentration' revolution in retinol delivery.

In other words, US5851538's Microsponge® technology functioned as the core retinol delivery technology for 20 years from its 1998 Grant to its 2018 Expire, and its expiration synchronized with the popularization of an era where 'high-concentration retinol can be safely formulated.'

Why was this patent mis-registered as 'P&G niacinamide' in the DB

At the time of writing this memo, the candidates.tsv authoring process (secondary source citation history) cannot be fully tracked, but three hypotheses hold.

1. Mixing in textbooks / industry articles: When other researchers cited a P&G cosmetic delivery patent of the same 1998-grant era, descriptions confusing APS Microsponge® systems and P&G systems existed in secondary sources, which flowed into candidates.tsv.
2. Same-era assignee patterns: 1998-2001 was a period when P&G niacinamide whitening research (later US5939082 Bissett filed 1996) and APS Microsponge® retinol (filed 1995) were grouped together as 'late-1990s cosmetic delivery innovations,' so the patent number / assignee correspondence was confused at recording.
3. Simple number input error: When entering the correct patent number for 'P&G niacinamide whitening' (candidate US5939082) into candidates.tsv, US5851538 from an adjacent file / material was mistakenly copied.

Decisive backup verification of any hypothesis is currently impossible; identifying the original secondary source is needed alongside Day 22+ P&G niacinamide re-excavation (Claim 1 verbatim retrieval of US5939082).

Day 22+ excavation candidates

Three excavation candidates derived from this memo are proposed for the cosmetic subseries Phase 2 'delivery patents' track.

1. APS Microsponge® base patent: US5851538 is an application example (retinol) patent. The base patent for Microsponge® itself is presumed to be US4690825 (Won, 1987). Retrieve this and translate Claim 1 verbatim into cosmetic context.
2. Retin-A Micro 0.1% gel regulatory approval-related patent group: Claim 1 verbatim retrieval from US patent group accompanying FDA approval (1997) (candidates US5,955,109 etc.).
3. DECIEM / The Ordinary Retinol 1% delivery form patentability: Primary-source retrieval of whether the 2017-released DECIEM Retinol 1% in Squalane adopts Microsponge / Polytrap / Microcapsule, or simple non-patented dispersion form.

These are proposed for addition to candidates.tsv as the candidate list when starting cosmetic delivery patent Phase 2 in Day 22+ (Google Sheets direct input not available; handed off to Haruko).